Background {#Sec1}
==========

Tigecycline was the first member in the glycylcycline class of antibacterial agents to be used clinically. It was approved by the US Food and Drug Administration (FDA) for the treatment of complicated skin and skin-structure infections (cSSSIs). Furthermore, it can be used for the treatment of complicated intra-abdominal infections (CIAI) caused by susceptible Gram-positive, Gram-negative and anaerobic organisms \[[@CR1]\]. Tigecycline is a structural derivative of minocycline sharing similar pharmacokinetic properties and adverse effects with tetracyclines. The most common adverse effects associated with tigecycline are nausea, vomiting and diarrhea. Pancreatitis has been found to be associated with tetracycline. However, it was not listed as an adverse drug reaction in the product label when tigecycline was originally approved. A subsequent retrospective cohort analysis and a review of phase 3 and 4 comparative studies of tigecycline have also been performed with mixed conclusions \[[@CR2], [@CR3]\]. As tigecycline has a broad spectrum, it has been used as part of the antimicrobial regimen for complicated infections in patients who had received an organ transplant. We report a case of tigecycline-induced acute pancreatitis after kidney transplantation and review the relevant literature.

Case presentation {#Sec2}
=================

A 48-year-old woman with end-stage renal disease (ESRD) due to chronic glomerulonephritis received a kidney transplant from a donor with DCD (donated cardiac death). The kidney was successfully transplanted to the recipient and normal serum creatinine levels were observed after 7 days. On the fourth day after transplantation, the patient was treated with teicoplanin, cefoperazone, sulbactam and etimicin due to the development of multiple drug resistance *Acinetobacter baumannii* in both organ preservation solution and drainage fluid. Tigecycline was administered intravenously at 100 mg for the first dose and was given at 50 mg every 12 h from the eighth day after the operation because of persistent abdominal infection*.* She felt pain at the transplant kidney area and then the blood pressure dropped to 88/61 mmHg on the twentieth day after transplantation. Emergency ultrasound showed two huge hematoma around the graft. Graft pain relieved after emergency treatment including transplanted kidney exploration, renal hematoma removal, renal vascular reconstruction and ureteral re-implantation. The treatment with tigecycline was continued based on the results of the peritoneal drainage, blood and urine culture. The symptoms did not worsen until approximately 15 days after being initially administered. The patient presented with fever, nausea, vomiting and moderate abdominal pain. Physical examination found moderate tenderness in the upper abdomen. Laboratory analyses were remarkable for leukocytosis and the level of lipase raised to 156 U/L. Other results such as serum amylase level was 424 U/L and drainage amylase was 554 U/L, despite the aminotransferase and alkaline phosphatase were within the normal range. CT scans (Fig. [1a](#Fig1){ref-type="fig"}) suggested acute pancreatitis (AP) with grade D on Balthazar score, no necrosis visible without contrast injection. There was no sign of dilated biliary ducts according to the abdominal ultrasound examination. Since those findings were considered to be related to drug-induced pancreatitis, it was recommended that tigecycline should be discontinued on the 16th day following exposure. Shortly after tigecycline discontinuation, the patient's symptoms gradually improved. Blood amylase and lipase returned to baseline levels in a week. CT scans (Fig. [1b](#Fig1){ref-type="fig"}) showed a basically normal after tigecycline discontinuation for 14 days. She was discharged from the hospital with a low-fat diet for 3 weeks. One month later, abdominal CT scans on follow-up did not find any abnormalities and showed as normal (Fig. [1c](#Fig1){ref-type="fig"}). Throughout the course of treatment, the immunosuppressive regimen was a triple therapy based on recommended doses including tacrolimus, mycophenolate mofetil and prednisone. Serum tacrolimus concentration was maintained at 6--8 ng/ml. The patient received these medications over the next 6 months, with no discomfort and relapse after stopping tigecycline. Timeline of disease was showed in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.Fig. 1image of CT scan during the the whole course of AP. **a** Twentie-five days post transplantation, the CT scan of abdomen showed pancreatic swelling, peripheral exudate effusion, considered acute pancreatitis (grade D on Balthazar score, no necrosis visible without contrast injection) after tigecycline treatment for 20 days. **b** scan showed a basically normal after tigecycline discontinuation for 14 days. **c** CT reported a normal finding after tigecycline discontinuation for 58 days

Discussion {#Sec3}
==========

Infection from DCD donors is a major challenge in China. A recent study from China showed that 19.4% of donor blood cultures showed blood infection, consistent with the literature that about 5% -11.3% of donors did not find bacteremia on donation. Data from this single-center showed that the incidence of donor-derived bacterial infection was 4.5% \[[@CR4], [@CR5]\]. Because this patient's donor-associated pathogen was multidrug-resistant *Acinetobacter baumannii*, we added tigecycline to the antibiotic regimen based on Chinese expert consensus \[[@CR6]\].

Tigecycline is the first member of a new class of antibiotics called glycylcyclines which was licensed by the US FDA in June 2005 for intravenous (IV) use in adults \[[@CR7]\]. It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit with a five-fold higher affinity than tetracycline \[[@CR8]\]. Tigecycline is a derivative of minocycline, with a 9-t-butylglycylamido group added to the 1st carbon on the D ring of minocycline and it possesses a broad spectrum range. In 2008, tigecycline received FDA's approval for the treatment of adult patients with community-acquired bacterial pneumonia \[[@CR9]\]. In vitro studies demonstrated that tigecycline exhibits a high level of antimicrobial activity against many common types of respiratory bacteria, including multiple resistant Gram-positive, Gram-negative, anaerobic, as well as multi-drug-resistant (MDR) pathogens, such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* \[[@CR10]\], penicillin-resistant *Streptococcus pneumoniae* (PRSP), methicillin-resistant *Staphylococcus epidermidis* (MRSE) and β-lactamase-producing *Haemophilus influenzae* \[[@CR11]\].

The most common adverse effects associated with tigecycline are nausea, vomiting and diarrhea. Pancreatitis has been reported that it could be induced by tetracycline, but it was not listed as an adverse drug reaction in the product label when tigecycline was originally approved. Concerns about tigecycline-induced AP have been raised by the clinicians in nearly 10 years \[[@CR12]--[@CR14]\]. Therefore, the former manufacturer of tigecycline, Wyeth, updated the product label including AP as one of the post-marketing adverse events in July 2006 \[[@CR1]\]. Interestingly, although tigecycline was registered as a treatment for CIAI, it shoule be used causally when infectious complications were associated with acute pancreatitis because of the possible tigecycline--induced pancreatitis. This exclusion criteria might have emerged due to the similarities between tigecycline and other tetracyclines.

Biliary tract disease (40%) and alcohol exposure (35%) are common causes of AP. Other etiologies include idiopathic pancreatitis, post-endoscopic retrograde cholangiopancreatography, trauma, medications, infection, hypercalcemia, hypertriglyceridemia, tumor and autoimmune diseases. Several drugs are associated with AP. The overall incidence of drug-induced AP is 0.1% \~ 2% \[[@CR15]\]. Medications associated with pancreatitis include tetracyclines, isoniazid, macrolides, metronidazole, propofol, angiotensin-converting enzyme inhibitors (ACEI), etc. \[[@CR16]\].

The cause of drug-induced pancreatic injury is unknown. By using the classification of Zimmerman originally described for drug hepatotoxicity, drugs associated with tissue-specific injury can be divided into those with intrinsic toxicity in the organ involved and those that cause injury as a result of host idiosyncrasy \[[@CR17]\]. As opposed to intrinsic toxicity, idiosyncratic reaction appears to be the mechanism of drug injury in the vast majority of cases. It is known that erythromycin stimulates motilin release which may induce AP by causing spasms of the sphincter of Oddi, leading to an abrupt of hypertension in the pancreatic duct and pancreatitis \[[@CR18]\]. Unlike the erythromycin cause the host idiosyncrasy, the mechanism of tetracycline-induced pancreatitis is still unknown. There have been at least three mechanisms hypothesized, including formation of a toxic metabolite, hypertriglyceridemia and a high biliary concentration \[[@CR12], [@CR19], [@CR20]\]. Tigecycline is structurally related to minocycline and shares similar pharmacokinetic properties and side effects with tetracyclines \[[@CR21]\]. The diagnosis of drug-induced AP is difficult to establish, mainly due to the absence of cause-specific diagnostic tests. Therefore, it is usually based on the following criteria: (1) AP occurs during the administration of a drug. \[[@CR22]\] All other common causes are excluded. (3) Symptoms of AP disappear after drug withdrawal. (4) Symptoms recur after a rechallenge of the suspected drug \[[@CR23]\]. A total of 10 literatures were collected from the database, which met the above inclusion criteria, involving a total of 12 cases with 13 occasions. \[[@CR12]--[@CR14], [@CR16], [@CR21], [@CR24]--[@CR27]\]. (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) At the same time, the included literature should include the general condition, past history, clinical manifestations of acute pancreatitis, CT scan, daily dose, combination drug therapy, symptom relief time, recovery time, medication time, enzyme recovery time and other information.Table 1Review of cases report of tigecycline-induced acute pancreatitis \-\-- demographic data and drug characteristicsAuthorCountryNumber of casesYear of reportAge of patientGenderIndication of tigecyclineCulture of specimensDuration of tigecycline (days)Daily dose (mg)Combination drugHitory of liver diseaseGlison MFrance1200835MaleChronic osteitis complicated by pseudarthritis*Enterobacter cloacae* with broad-spectrum betalactamase15100Imipenem, amikacinNoneLipshitz JUsa1200964FemaleProsthetic joint infectionNA14100Levothyroxine,NoneMarshall RSUSA1200955FemaleSoft Tissue InfectionEnterococcus faecalis, Pseudomonas aeruginosa, and Staphylococcus hominis14NAPantoprazole, and hydromorphone.NoneHung WYUSA1200969FemaleSoft tissue infection/vascular graft infectionCoagulase-negative Staphylococcus, *Staphylococcus epidermidis* and diphtheroids, Clostridium difficile8100Meropenem, vancomycin, clindamycinNoneProt-Labarthe SFrance120109MaleBacteriemia / arthritisEnterobacter cloacae producing extended spectrum betalactamase56100Colistin, amikacin and rifampinNoneOtero RSMexico1201027FemaleAcute pneumoniaNA7100Amikacin, oseltamivirNoneMascarello MItaly12012NANAChronic osteomyelitismethicillin-resistant *Staphylococcus aureus*, multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii12100Amikacin, propofolNoneHemphill MTUSA1st201522MaleAcute bronchitisM. chelonae14NATobramycin, meropenem, and vancomycinNoneHemphill MTUSA2nd201522MaleAcute bronchitisM. chelonae3NAAmikacin, clarithromycinNoneMarot JCBelgiumcase 1201264MaleSoft tissue infectionStaphylococcus aureus6100NoneNoneMarot JCBelgiumcase 2201258MaleSoft tissue infection/osteomyelitisStaphyloccus scleiferi methicillin-resistant and Staphylococcus lugdunensis methicillin-sensitive8100Piperacillin-Tazobactam, VancomycinNoneDavido BFranceCase 1201670MalePyelonephritisESBL *Escherichia coli*6100NoneNoneDavido BFranceCase 2201650FemaleFemoral osteomyelitisEBSL *E. coli*,20100Imipenem amikacin.None*NA* not availableTable 2Review of cases report of tigecycline-induced acute pancreatitis \-\-- Clinical findings of casesAuthorOnset of symptomsClinical manifestationAmylase/Lipase levels (u/L)CRP (mg/l)CT scanAP severityTime to symptoms relieved (days)Time to recovery of enzymes (days)Glison M13 days, abdominal painAcute abdominal 'stab-like' pain(−)/100035Pancreatic oedema without any necrotic flows (Balthazar Stage 1).Mild243Lipshitz J14 days, epigastric painNausea, vomiting, abdominal pain806/1406NAMild inflammatory stranding about the duodenum and minimal fluid in the left retroperitoneum.Mild35Marshall RS3 days, uncontrolled emesisNausea, vomiting, fever and loss of appetite180/156NAAcute pancreatitisMild27Hung WY3 days, nausea and vomitingPersistent and worsening nausea and vomiting, abdominal pain926/749NANANA35Prot-Labarthe S14 days, abdominal painAbdominal pain, recurrent vomiting(−)/603NAInflammation involving pancreas and peripancreatic fat without necrosis (Ranson Score 2 and Balthazar stage 2).Mild35Otero RS7 daysNausea, vomiting, epigastric pain, distention255/424NAPancreatic enlargement, low density shadow of pancreas tail (grade D on Balthazar score)Mild312Mascarello M12 daysNausea, vomiting and acute severe upper abdominal pain312/382131Inflammation of the pancreas and peripancreatic fat, necrosis of 40% of the pancreatic gland, peripancreatic stranding, and fluid collection (Balthazar CT severity index 7).severe≤10≤10Hemphill MT10 daysAbdominal painNA/732NAAcute pancreatitisMild66Hemphill MT3 daysMild nausea, epigastric tenderness381/268NAAcute pancreatitisMild55Marot JC6 days, epigastric painNausea, epigastric pain750/936NAAn oedematous pancreatitis (grade D on Balthazar score)Mild418Marot JC7 days, abdominal pain on day 8Nausea, vomiting and loss of appetite552/1660NAAcute pancreatitis, no necrosis visible without contrast injection (grade D on Balthazar score)Mild54Davido B6 days,Anorexia, vomiting and abdominal discomfortNA/ 2460NATypical oedematous infiltrate (Balthazar A).Mild22Davido B20 daysNausea, abdominal discomfortNA/ 1340NANANA11*CT* Computerized Tomography, *AP* Acute Pancreatitis, *CRP* C-Reactive Protein

Tetracycline-induced AP is closely related to the underlying liver disease in patients \[[@CR20], [@CR28]\]. For patients without a history of liver disease, the onset of AP caused by tetracycline for anti-infection therapy ranged from 4 months to 2 years with an average total daily dose of 1083 \~ 1353 mg/d. However, for those patients with severe hepatic dysfunction, the course of tetracycline lasted for 8\~ 17 days with an average total daily dose of 1500 \~ 4000 mg/d \[[@CR29]\]. Recovery time of amylase and lipase to the normal range was within 13 \~ 21 days. In our review, the administration of tigecycline for the 12 patients was all in accordance with the specification, which indicated that there was no significant correlation between AP and medication. If patients had no history of liver disease, tigecycline-induced acute pancreatitis was more rapid compared to tetracycline. Meanwhile, after withdrawal of tigecycline, the symptoms were relieved more quickly and the time for serum lipase and amylase decline was also shorter.

Twelve patients were given anti-infective drug combination therapy. Moreover, most of the drugs for discontinuation of tigecycline were still used continually. In some cases, propofol increases serum triglyceride levels and may cause AP. However, the patient did not have any hyperlipidemia, and neither of the previous propofol uses caused pancreatitis \[[@CR30]\]. There was no evidence that aggravating pancreatitis was associated with propofol combination therapy. Our patient was taking several additional drugs possibly. However, during treatment or ceasing of tigecycline, she has been taking these medications at recommended dose which were associated with pancreatitis and classified as group III (prednisone) and group IV (tacrolimus), respectively (low risk) \[[@CR18]\]. Therefore, we do not think that combination therapy in this situation may lead to acute pancreatitis.

The increasing degree of amylase and lipase is not directly related to the severity of AP. Lipshitz J et al. reported the serum lipase and the amylase were as high as 806 UI/L and 1406 UI/L in patients with abdominal pain associated with nausea and vomiting, while CT scans showed duodenal mild inflammation and left posterior abdominal effusion \[[@CR13]\]. However, Mascarello M et al. reported that serum lipase and amylase were 382 UI/L and 312 UI/L respectively in patients with similar symptoms \[[@CR31]\]. CT scans showed severe pancreatitis inflammation with 40% pancreatic and peripancreatic necrosis and fluid retention, and the Balthazar classification was E level with CTSI score 7 points. It should be noted that the final time to normalize serum lipase and amylase was not directly related to serum lipase and amylase levels.

Finally, tigecycline induced AP is still considered to be a rare phenomenon. However, serum amylase and lipase levels should be closely monitored if any symptomatic abdominal pain suggests AP during treatment. In addition, the mechanism of tigecycline-induced AP and the possibility of cross-reactivity with tetracycline in patients with AP induced by tigecycline should be given more attention.Whether tigecycline increases the risk of pancreatitis in immunosuppressed recipients requires more research data.

Conclusions {#Sec4}
===========

Clinicians should pay attention to clinical signs and symptoms and the level of pancreatic enzymes in the blood in order to monitor the development of pancreatitis. Abdominal CT images should be taken on a regular basis when necessary for the administration of tigecycline.
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===============
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